CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Altovida Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Altovida Inc
Biocity Scotland, Bo'Ness Road
Phone: +44 1698539797p:+44 1698539797 MOTHERWELL, ML1 5UH  United Kingdom

This company was Merged or Acquired on 1/16/2014.
Acquired by ES Partners, Ltd.
This company is no longer actively traded on any major stock exchange.

Business Summary
Altovida, Inc., formerly Remmington Enterprises, Inc., is a biopharmaceutical company focused on the development and commercialization of medicines in areas of real clinical need. The Company operates through its wholly owned subsidiary, Altovida Biosciences Limited, based in Scotland, the United Kingdom. The Company’s development portfolio includes five medicines, which the Company is working to bring to market in the United States and Europe. The Company has two lead products: ALT022, used for the treatment of opioid overdos, and ALT025, used for the sedation and the treatment of acute seizures. The Company’s pipeline of products also includes ALT011, ALT024 and ALT013. ALT011 is used for the treatment for constipation. ALT024 offers the treatment of Amyotrophic Lateral Sclerosis (ALS) benefitting both patients and caregivers. ALT013 offers treatment for Parkinson’s disease (PD), which is a neurodegenerative disorder.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
IRA CQ
Score
Moody's
Rating
Fitch
Rating
DBRS
Rating
Morningstar
Rating
-Yes-------

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
10/31/20147/31/2014YesYes---

Industries
SIC Code Description
6726 Unit investment trusts, face-amount certificate offices

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board VinodKaushal 50 5/2/2014 5/2/2014
President, Chief Executive Officer, Director Michael R.Hawthorne 40 5/2/2014 5/2/2014
Chief Financial Officer, Treasurer, Secretary, Director Lorna A.Peers 45 5/2/2014 5/2/2014

General Information
Number of Employees: 5 (As of 7/31/2014)
Outstanding Shares: 77,650,166 (As of 12/1/2014)
Shareholders: 5
Stock Exchange: OTC
Federal Tax Id: 452759045


Copyright © 2019 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, November 19, 2019